Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Lisco, Giuseppe, De Tullio, Anna, Disoteo, Olga, Piazzolla, Giuseppina, Guastamacchia, Edoardo, Sabbà, Carlo, De Geronimo, Vincenzo, Papini, Enrico, Triggiani, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563602/
https://www.ncbi.nlm.nih.gov/pubmed/37656509
http://dx.doi.org/10.1530/EC-23-0257
_version_ 1785118367654346752
author Lisco, Giuseppe
De Tullio, Anna
Disoteo, Olga
Piazzolla, Giuseppina
Guastamacchia, Edoardo
Sabbà, Carlo
De Geronimo, Vincenzo
Papini, Enrico
Triggiani, Vincenzo
author_facet Lisco, Giuseppe
De Tullio, Anna
Disoteo, Olga
Piazzolla, Giuseppina
Guastamacchia, Edoardo
Sabbà, Carlo
De Geronimo, Vincenzo
Papini, Enrico
Triggiani, Vincenzo
author_sort Lisco, Giuseppe
collection PubMed
description Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
format Online
Article
Text
id pubmed-10563602
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-105636022023-10-11 Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? Lisco, Giuseppe De Tullio, Anna Disoteo, Olga Piazzolla, Giuseppina Guastamacchia, Edoardo Sabbà, Carlo De Geronimo, Vincenzo Papini, Enrico Triggiani, Vincenzo Endocr Connect Review Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue. Bioscientifica Ltd 2023-09-01 /pmc/articles/PMC10563602/ /pubmed/37656509 http://dx.doi.org/10.1530/EC-23-0257 Text en © the author(s) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Lisco, Giuseppe
De Tullio, Anna
Disoteo, Olga
Piazzolla, Giuseppina
Guastamacchia, Edoardo
Sabbà, Carlo
De Geronimo, Vincenzo
Papini, Enrico
Triggiani, Vincenzo
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title_full Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title_fullStr Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title_full_unstemmed Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title_short Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
title_sort glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563602/
https://www.ncbi.nlm.nih.gov/pubmed/37656509
http://dx.doi.org/10.1530/EC-23-0257
work_keys_str_mv AT liscogiuseppe glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT detullioanna glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT disoteoolga glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT piazzollagiuseppina glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT guastamacchiaedoardo glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT sabbacarlo glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT degeronimovincenzo glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT papinienrico glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned
AT triggianivincenzo glucagonlikepeptide1receptoragonistsandthyroidcancerisitthetimetobeconcerned

Ejemplares similares